Bioengineered bacterial outer membrane vesicles as cell-specific drug-delivery vehicles for cancer therapy

Cited 346 time in scopus
Metadata Downloads
Title
Bioengineered bacterial outer membrane vesicles as cell-specific drug-delivery vehicles for cancer therapy
Author(s)
V Gujrati; S Kim; Sang-Hyun Kim; J J Min; H E Choy; S C Kim; S Jon
Bibliographic Citation
ACS Nano, vol. 8, no. 2, pp. 1525-1537
Publication Year
2014
Abstract
Advances in genetic engineering tools have contributed to the development of strategies for utilizing biologically derived vesicles as nanomedicines for achieving cell-specific drug delivery. Here, we describe bioengineered bacterial outer membrane vesicles (OMVs) with low immunogenicity that can target and kill cancer cells in a cell-specific manner by delivering small interfering RNA (siRNA) targeting kinesin spindle protein (KSP). A mutant Escherichia coli strain that exhibits reduced endotoxicity toward human cells was engineered to generate OMVs displaying a human epidermal growth factor receptor 2 (HER2)-specific affibody in the membrane as a targeting ligand. Systemic injection of siRNA-packaged OMVs caused targeted gene silencing and induced highly significant tumor growth regression in an animal model. Importantly, the modified OMVs were well tolerated and showed no evidence of nonspecific side effects. We propose that bioengineered OMVs have great potential as cell-specific drug-delivery vehicles for treating various cancers.
Keyword
affibodycancer therapydrug deliveryouter membrane vesiclessiRNA
ISSN
1936-0851
Publisher
Amer Chem Soc
DOI
http://dx.doi.org/10.1021/nn405724x
Type
Article
Appears in Collections:
1. Journal Articles > Journal Articles
Files in This Item:
  • There are no files associated with this item.


Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.